The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease
Public ClinicalTrials.gov record NCT02546609. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients
Study identification
- NCT ID
- NCT02546609
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- NuSirt Biopharma
- Industry
- Enrollment
- 91 participants
Conditions and interventions
Conditions
Interventions
- Leu-Met-Sil 0.5 Drug
- Leu-Met-Sil 1.0 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2015
- Primary completion
- Nov 29, 2016
- Completion
- Jan 30, 2017
- Last update posted
- May 1, 2018
2015 – 2017
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Catalina Research Institute | Chino | California | 91710 | — |
| University of California San Diego | San Diego | California | 92103 | — |
| Rocky Mountain Research | Wheat Ridge | Colorado | 80033 | — |
| Atlanta Gastroenterology Associates | Atlanta | Georgia | 30312 | — |
| GI Specialists of Georgia | Marietta | Georgia | 30060 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| University of North Carolina Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Sterling Research | Cincinnati | Ohio | 45246 | — |
| Premier Clinical Research | Clarksville | Tennessee | 37043 | — |
| Gastro One | Germantown | Tennessee | 38138 | — |
| Quality Medical Research | Nashville | Tennessee | 37211 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02546609, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 1, 2018 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02546609 live on ClinicalTrials.gov.